Facile generation of biepitopic antibodies with intrinsic agonism for activating tumor necrosis factor receptors.
Cell Chem Biol
; 31(5): 944-954.e5, 2024 May 16.
Article
en En
| MEDLINE
| ID: mdl-38653243
ABSTRACT
Agonist antibodies are being pursued for therapeutic applications ranging from neurodegenerative diseases to cancer. For the tumor necrosis factor (TNF) receptor superfamily, higher-order clustering of three or more receptors is key to their activation, which can be achieved using antibodies that recognize two unique epitopes. However, the generation of biepitopic (i.e., biparatopic) antibodies typically requires animal immunization and is laborious and unpredictable. Here, we report a simple method for identifying biepitopic antibodies that potently activate TNF receptors without the need for additional animal immunization. Our approach uses existing, receptor-specific IgGs, which lack intrinsic agonist activity, to block their corresponding epitopes, then selects single-chain antibodies that bind accessible epitopes. The selected antibodies are fused to the light chains of IgGs to generate human tetravalent antibodies. We highlight the broad utility of this approach by converting several clinical-stage antibodies against OX40 and CD137 (4-1BB) into biepitopic antibodies with potent agonist activity.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Epítopos
Límite:
Animals
/
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article